Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with concurrent chemoradiotherapy for small cell lung cancer
ChiCTR2100048285Phase 4Not yet recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in small cell lung cancer (SCLC) (2 arms), sponsored by Weihai Municipal Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100048285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048285.